NOVATEOR RESEARCH LABORATORIES LIMITED
NOVATEOR RESEARCH LABORATORIES LIMITED has informed BSE about Intimation on Agreements.
Novateor Research Laboratories Limited has informed the BSE about an intimation on agreements.
49
total announcements
542771.BO · 15 min delayed
NOVATEOR RESEARCH LABORATORIES LIMITED
Novateor Research Laboratories Limited has informed the BSE about an intimation on agreements.
NOVATEOR RESEARCH LABORATORIES LIMITED
Novateor Research Laboratories Limited has informed the exchange about intimation on agreements.
NOVATEOR RESEARCH LABORATORIES LIMITED
NOVATEOR RESEARCH LABORATORIES LIMITED has informed BSE about Intimation on Agreements, indicating a potential business expansion signal.
NOVATEOR RESEARCH LABORATORIES LIMITED
NOVATEOR RESEARCH LABORATORIES LIMITED has informed BSE about Intimation on Agreements.
NOVATEOR RESEARCH LABORATORIES LIMITED
NOVATEOR RESEARCH LABORATORIES LIMITED has informed BSE about Intimation on Agreements, indicating a potential business expansion signal.
NOVATEOR RESEARCH LABORATORIES LIMITED
Novateor Research Laboratories Limited has informed BSE about an intimation on agreements.
NOVATEOR RESEARCH LABORATORIES LIMITED
NOVATEOR RESEARCH LABORATORIES LIMITED has informed BSE about Intimation on Agreements.
NOVATEOR RESEARCH LABORATORIES LIMITED
Novateor Research Laboratories Limited has informed BSE about Intimation on Agreements, providing details on agreements.
NOVATEOR RESEARCH LABORATORIES LIMITED
NOVATEOR RESEARCH LABORATORIES LIMITED has informed BSE about Intimation on Agreements.
NOVATEOR RESEARCH LABORATORIES LIMITED
NOVATEOR RESEARCH LABORATORIES LIMITED has informed BSE about Intimation on Agreements.
NOVATEOR RESEARCH LABORATORIES LIMITED
Novateor Research Laboratories Limited has informed BSE about Intimation on Agreements.
NOVATEOR RESEARCH LABORATORIES LIMITED
Novateor Research Laboratories Limited has informed the exchange about an intimation on agreements.
NOVATEOR RESEARCH LABORATORIES LIMITED
NOVATEOR RESEARCH LABORATORIES LIMITED has informed BSE about Intimation on Agreements.
Novateor Research Laboratories Ltd
Novateor Research Laboratories Ltd has entered into a three-year supply agreement with Pidilite Industries Ltd for the exclusive development, manufacture, packing, and supply of Aligner Cleaning Foam and Tooth Brightening Strips.
Novateor Research Laboratories Ltd
Novateor Research Laboratories Ltd has informed BSE that as a company listed on the SME platform, it is exempt from disclosing related party transactions under Regulation 23(9) of SEBI (LODR) Regulations, 2015, for the half year ended September 30, 2024.
Novateor Research Laboratories Ltd
Novateor Research Laboratories Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, confirming the details of securities dematerialized/rematerialized during the quarter ended September 30, 2026, to the BSE.
Novateor Research Laboratories Ltd
Novateor Research Laboratories Ltd has announced the Scrutinizer Report for the 15th Annual General Meeting, where resolutions related to audited financial statements, director reappointment, and shifting of registered office were passed with 100% voting in favour. Related party transactions with Mr. Navdeep Mehta were also approved with 100% voting in favour, but with some votes excluded due to conflict of interest.
Novateor Research Laboratories Ltd
Novateor Research Laboratories Ltd has announced the closure of its trading window for all directors, designated persons, and their immediate relatives from October 1, 2026, until 48 hours after the announcement of its half-yearly financial results for September 30, 2026.
Novateor Research Laboratories Ltd
Novateor Research Laboratories Ltd has informed BSE about change in its registered office address from Ahmedabad to Sanand, Gujarat, effective October 01, 2026, as approved by its 15th AGM on September 29, 2026.
Novateor Research Laboratories Ltd
Novateor Research Laboratories Ltd held its 15th Annual General Meeting on September 29, 2026, where six resolutions were passed, including the adoption of financial statements, reappointment of a director, and authorization for related party transactions.